SEARCH:   Advanced

Blood, 1 January 2007, Vol. 109, No. 1, pp. 58-60. Prepublished online as a Blood First Edition Paper on September 14, 2006; DOI 10.1182/blood-2006-03-011239. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-03-011239v1 109/1/58    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rousselot, P. Articles by Mahon, F.-X. Search for Related Content PubMed PubMed Citation Articles by Rousselot, P. Articles by Mahon, F.-X. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 21, 2006 Accepted July 6, 2006 Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years Philippe Rousselot, Francoise Huguet, Delphine Rea, Laurence Legros, Jean Michel Cayuela, Odile Maarek, Odile Blanchet, Gerald Marit, Eliane Gluckman, Josy Reiffers, Martine Gardembas, and Francois-Xavier Mahon* Federation d'hematologie et Centre d'Investigation Clinique, Hopital Saint-Louis, Paris, France Service d'Hematologie, Hopital de Purpan, Toulouse, France Service d'hematologie, Hopital Larchet, Nice, France Laboratoire Central d'Hematologie, INSERM U728, Hopital Saint-Louis, Paris, France Laboratoire d'hematologie, CHU d'Angers, Angers, France Service des Maladies du Sang, CHU du Haut Leveque, Pessac Institut Bergonie, Bordeaux, France Service d'Hematologie, CHU d'Angers, Angers Laboratoire Hematopoiese normale et pathologique, Universite Victor Segalen,Bordeaux 2, INSERM E217 * Corresponding author; email: francois-xavier.mahon{at}umr5540.u-bordeaux2.fr. In the present study, we address the issue of the discontinuation of imatinib in chronic myelogenous leukaemia with undetectable residual disease for more than 2 years. Twelve patients were included. The median duration of RTQ-PCR negativity and imatinib therapy were respectively 32 months (24-46) and 45 months (32-56) before imatinib interruption. Six patients displayed a molecular relapse with a detectable BCR-ABL transcript at respectively 1, 1, 2, 3, 4 and 5 months. Imatinib was then re-introduced and led to a novel molecular response in most patients. Six other patients (50%) have still an undetectable level of BCR-ABL transcript after a median follow up of 18 months (9-24). We hypothesize that relapses observed within 6 months reflects the kinetic of undetectable dividing CML cells. Those cells may be eradicated or controlled in long term non relapsing patients described in our study. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. A. Sipkins Rendering the Leukemia Cell Susceptible to Attack N. Engl. J. Med., September 24, 2009; 361(13): 1307 - 1309. [Full Text] [PDF] E. Mattarucchi, O. Spinelli, A. Rambaldi, F. Pasquali, F. Lo Curto, L. Campiotti, and G. Porta Molecular Monitoring of Residual Disease in Chronic Myeloid Leukemia by Genomic DNA Compared with Conventional mRNA Analysis J. Mol. Diagn., September 1, 2009; 11(5): 482 - 487. [Abstract] [Full Text] [PDF] M. Baccarani, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv105 - iv107. [Full Text] [PDF] A. Hayat, S. R. McCann, S. Langabeer, S. Irvine, M. F. McMullin, and E. Conneally Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation Haematologica, February 1, 2009; 94(2): 296 - 298. [Full Text] [PDF] J. M. Goldman Chronic Myeloid Leukemia Stem Cells: Now on the Run J. Clin. Oncol., January 10, 2009; 27(2): 313 - 314. [Full Text] [PDF] T. O'Hare and M. W. Deininger Toward a Cure For Chronic Myeloid Leukemia Clin. Cancer Res., December 15, 2008; 14(24): 7971 - 7974. [Full Text] [PDF] H. Konig, M. Copland, S. Chu, R. Jove, T. L. Holyoake, and R. Bhatia Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells Cancer Res., December 1, 2008; 68(23): 9624 - 9633. [Abstract] [Full Text] [PDF] H.-J. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood, December 1, 2008; 112(12): 4371 - 4383. [Abstract] [Full Text] [PDF] D. Marin, D. Milojkovic, E. Olavarria, J. S. Khorashad, H. de Lavallade, A. G. Reid, L. Foroni, K. Rezvani, M. Bua, F. Dazzi, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood, December 1, 2008; 112(12): 4437 - 4444. [Abstract] [Full Text] [PDF] F.-X. Mahon, F. Huguet, F. Guilhot, L. Legros, F. E Nicolini, A. Charbonnier, A. Guerci, D. Rea, B. R. Varet, M. Gardembas, et al. Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre << Stop Imatinib >> (STIM) Study Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 187 - 187. [Abstract] J. E. Cortes Imatinib Therapy for Chronic Myeloid Leukemia: Where Do We Go Now? J. Clin. Oncol., July 10, 2008; 26(20): 3308 - 3309. [Full Text] [PDF] S. M. Pye, J. Cortes, P. Ault, A. Hatfield, H. Kantarjian, R. Pilot, G. Rosti, and J. F. Apperley The effects of imatinib on pregnancy outcome Blood, June 15, 2008; 111(12): 5505 - 5508. [Abstract] [Full Text] [PDF] M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF] M. W.N. Deininger Imatinib Resistance and the Difficulty of Eradicating Leukemia Stem Cells ASCO Educational Book, January 1, 2008; 2008(1): 318 - 323. [Abstract] [Full Text] [PDF] S. Branford, J. F. Seymour, A. Grigg, C. Arthur, Z. Rudzki, K. Lynch, and T. Hughes BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria Clin. Cancer Res., December 1, 2007; 13(23): 7080 - 7085. [Abstract] [Full Text] [PDF] A. D. Klion, J. Robyn, I. Maric, W. Fu, L. Schmid, S. Lemery, P. Noel, M. A. Law, M. Hartsell, C. Talar-Williams, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing Blood, November 15, 2007; 110(10): 3552 - 3556. [Abstract] [Full Text] [PDF] J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] C. A. Schiffer BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia N. Engl. J. Med., July 19, 2007; 357(3): 258 - 265. [Full Text] [PDF] S. Branford Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice Hematology, January 1, 2007; 2007(1): 376 - 383. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020